A novel murine model of allogeneic vaccination against renal cancer

OBJECTIVES To develop a murine model for whole‐cell allogeneic vaccination in renal cancer, as such vaccines aim to direct immune responses against patient tumour cells, due to shared antigens between the vaccine and tumour cells. MATERIALS AND METHODS A novel murine renal cell line, allogeneic to BALB/c, was developed from a C57BL/6 mouse by primary cell culture (RVIK). It was immortalized by HPV16 E6/E7 and transfected with ras in an attempt to improve its immunogenicity. The cell line was characterized and tested as a vaccine in a BALB/c tumour‐protection model after subsequent tumour challenge with autologous RenCa tumour cells. RESULTS RVIK alone, with no ras induced cross‐reactive immunity, providing a valid non‐tumorigenic allogeneic whole‐cell vaccine model for renal cancer. Ras transfection per se did not improve RVIK immunity. CONCLUSIONS RVIK is a novel immunogenic murine renal epithelial cell line, which confers protection when used as an allogeneic vaccine. It provides proof of principle for the effectiveness of allogeneic whole‐cell vaccines and may therefore form the basis of a useful model of allogeneic vaccination to further optimize vaccination schedules, formulation and adjuvants for a clinical setting.